CSF somatostatin in Alzheimer's disease

Michael Serby, Stephen B. Richardson, Sally Twente, Joanna Siekierski, June Corwin, John Rotrosen

Research output: Contribution to journalArticlepeer-review

50 Scopus citations

Abstract

Studies have previously demonstrated low somatostatin levels in autopsy cortical tissue from Alzheimer's disease (AD) patients and low somatostatin levels in CSF obtained from subjects with dementia. We evaluated levels of this peptide in 21 non-depressed subjects, 10 with AD, 2 with Parkinson's disease (PD), and 9 with other neurological conditions. The AD patients had significantly lower mean CSF somatostatin than the "other" neurological patients (14.6±1.5 S.E.M. versus 26.7±3.2 pg/ml, p<0.005). A demented PD subject had a level in the range of the AD group, while the non-demented PD patient had a value above this range. Thus, all 11 patients with AD or PD dementia, analogous disorders, had levels below 21.8 mg/ml, while 7 of the 10 remaining patients had values above 21.8 pg/ml. Age did not explain this finding.

Original languageEnglish
Pages (from-to)187-189
Number of pages3
JournalNeurobiology of Aging
Volume5
Issue number3
DOIs
StatePublished - 1984
Externally publishedYes

Keywords

  • Alzheimer's disease
  • Dementia
  • Neuropeptides
  • Parkinsonian dementia
  • Somatostatin

Fingerprint

Dive into the research topics of 'CSF somatostatin in Alzheimer's disease'. Together they form a unique fingerprint.

Cite this